Orthosilicic Acid (ch-OSA) — The Bioavailable Silicon

Silicon in the form of orthosilicic acid (Si(OH)4) is the bioactive monomeric species that is absorbed from the gastrointestinal tract and distributed to connective tissues. In the dermis, silicon stimulates fibroblast collagen type I synthesis and upregulates the activity of prolyl hydroxylase, which is essential for the post-translational hydroxylation of proline to hydroxyproline — a modification required for collagen triple-helix stability and crosslinking. Silicon also activates glycosaminoglycan synthesis (including hyaluronic acid and chondroitin sulphate) in fibroblasts, contributing to dermal hydration and viscoelasticity. In bone, silicon stimulates osteoblast differentiation and bone matrix mineralisation. The choline-stabilised form (ch-OSA) prevents polymerisation of orthosilicic acid into insoluble silica polymers, maintaining the bioactive monomeric form through the gastrointestinal tract and achieving plasma silicon concentrations 3-fold higher than aqueous orthosilicic acid solutions.

A 2005 double-blind RCT in the Archives of Dermatological Research demonstrated that ch-OSA at 10 mg/day for 20 weeks significantly improved skin microrelief (-30% surface roughness), skin elasticity (+89% Ur/Uf ratio), and hair tensile strength (+13.1%) compared to placebo in women with fine hair and photo-aged skin. A 2007 RCT in the Journal of the International Society of Sports Nutrition confirmed that ch-OSA at 10 mg/day for 12 months significantly improved bone collagen formation markers (PINP) in women with osteopenia. These are among the most rigorous trials for any silicon supplement.

The clinically validated dose is 10 mg/day of elemental silicon as ch-OSA (BioSil), typically provided as 5 drops or 2 capsules of the standard formulation. Effects on skin and hair are typically observed after 16–20 weeks of consistent supplementation. Best taken in the morning with water, away from meals to maximise absorption. The choline component (approximately 100 mg per 10 mg silicon dose) contributes to the total choline intake and should be considered in individuals managing choline-sensitive conditions.

ch-OSA has an excellent safety profile in all published clinical trials. Orthosilicic acid is efficiently excreted by the kidneys, and excess silicon does not accumulate in soft tissues at supplemental doses. Individuals with severely compromised renal function should use caution due to reduced silicon excretion capacity. The choline component is safe at the doses provided and may be beneficial for individuals with low dietary choline intake. No significant drug interactions have been identified. Inhalation of crystalline silica dust (an occupational hazard) is entirely unrelated to oral orthosilicic acid supplementation.

Key Papers